drugset
drugset / Trial / NCT06069726

A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial

NCT06069726 ↗

Phase 2 Recruiting 80 enrolled Duke University
NaSingle-groupOpen-labelTreatment

Summary

This is to study if neoadjuvant atezolizumab therapy is beneficial for patients with recurrent glioblastoma and a low mutational burden.

Timeline

Start
2024-03-21
Primary completion
2028-01-01
Completion
2028-01-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Atezolizumab Monoclonal antibody — —

Indications

glioblastoma